CerSci Therapeutics Finds $225,000 From SBIR Grant

Dallas-based CerSci Therapeutics, a developer of non-opioid painkillers aimed at treating chronic neuropathic pain, has been awarded a $225,000 grant from the National Institutes of Health (NIH), the company reported this morning. The Phase I SBIR grant comes from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH), and will go towards continued development of its drug candidates. CerSci was founded in 2015. Its pipeline is based on adenosine monophosphate activated protein kinase (AMPK) activators and peroxynitrite (PN) scavengers.